【摘要】 背景与目的肺上皮-肌上皮癌(pulmonary epithelial-myoepithelial carcinoma, P-EMC)是一种十分罕见的涎腺型肺肿瘤,尚无标准治疗方案,本文拟分析肺上皮-肌上皮癌的临床特点,探讨肺上皮-肌上皮癌的诊疗方案。方法分析1例肺上皮-肌上皮癌患者的临床资料并回顾其他相关临床文献。结果上皮细胞免疫组化表达细胞角蛋白,肌上皮细胞免疫组化表达SMA及S-100,二代基因测序以HRAS基因突变为主,PD-L1蛋白为阴性。结论肺上皮-肌上皮癌大多预后良好,诊断以镜检及免疫组化为主,治疗以手术切除为主,放化疗效果尚不明确。更多还原

【Abstract】 Background and objective Pulmonary epithelial-myoepithelial carcinoma is a very rare type of salivary gland lung tumor. No standard treatment plan yet. This article intends to analyze the clinical characteristics of pulmonary epithelial-myoepithelial carcinoma and discuss the diagnosis and treatment of pulmonary epithelial-myoepithelial carcinoma. Methods The clinical data of a patient with pulmonary epithelial-myoepithelial carcinoma were analyzed and other relevant clinical literatures were reviewed. Results Epithelial cells immunohistochemically expressed cytokeratin and myoepithelial cells immunohistochemically expressed SMA and S-100. The next-generation sequencing was mainly HRAS gene mutation and the express of PD-L1 protein was negative. Conclusion Most of the patients with Pulmonary epithelial-myoepithelial carcinoma have a good prognosis. Diagnosis mainly depends on microscopic examination and immunohistochemistry. The treatment of pulmonary epithelial-myoepithelial carcinoma is mainly surgical resection. The effect of radiotherapy and chemotherapy is not clear.更多还原